Literature DB >> 19854095

The LRRK2 G2385R variant is a risk factor for sporadic Parkinson's disease in the Korean population.

Jong-Min Kim1, Jee-Young Lee, Hee Jin Kim, Ji Seon Kim, Eun-Soon Shin, Jin-Hwan Cho, Sung Sup Park, Beom S Jeon.   

Abstract

The G2385R (SNP accession no. rs34778348) and R1628P (rs33949390) variants of leucine-rich repeat kinase 2 (LRRK2, PARK8) are emerging as an important risk factor for Parkinson's disease (PD) in the ethnic Chinese and Japanese populations. The purpose of this study was to investigate whether these variants are a genetic risk factor in sporadic PD patients in the Korean population. A total of 923 patients and 422 healthy subjects were included. The variants were screened by a SNaPshot assay. The LRRK2 G2385R variant was detected in 82 PD patients (8.9%, two homozygous and 80 heterozygous) and in 21 normal controls (5.0%, all heterozygous). The frequency of the LRRK2 G2385R variant in PD was significantly higher than in normal controls (adjusted odds ratio 1.83, p = 0.0170, 95% confidence interval 1.11-3.00). There were no differences in the mean age at onset or gender between the G2385R carriers and the non-carriers in PD patients. The LRRK2 R1628P variant was very rare (0.78% in patients versus 0.26% in controls) in the tested 384 patient-control pairs, and was not a significant risk factor. This study supports that the LRRK2 G2385R variant may be a genetic risk factor for sporadic PD in the Korean population. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19854095     DOI: 10.1016/j.parkreldis.2009.10.004

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  20 in total

1.  Association between G2385R and R1628P polymorphism of LRRK2 gene and sporadic Parkinson's disease in a Han-Chinese population in south-eastern China.

Authors:  Jiangping Cai; Yi Lin; Wanjin Chen; Qifang Lin; Bin Cai; Ning Wang; Weihong Zheng
Journal:  Neurol Sci       Date:  2013-04-30       Impact factor: 3.307

Review 2.  Genetics of Parkinson disease and essential tremor.

Authors:  Christian Wider; Owen A Ross; Zbigniew K Wszolek
Journal:  Curr Opin Neurol       Date:  2010-08       Impact factor: 5.710

Review 3.  Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Authors:  Iakov N Rudenko; Mark R Cookson
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 4.  The association between the LRRK2 G2385R variant and the risk of Parkinson's disease: a meta-analysis based on 23 case-control studies.

Authors:  Cheng-Long Xie; Jia-Lin Pan; Wen-Wen Wang; Yu Zhang; Su-Fang Zhang; Jing Gan; Zhen-Guo Liu
Journal:  Neurol Sci       Date:  2014-07-16       Impact factor: 3.307

5.  LRRK2 G2385R variant carriers of female Parkinson's disease are more susceptible to motor fluctuation.

Authors:  Chao Gao; Hao Pang; Xiao-Guang Luo; Yan Ren; Hong Shang; Zhi-Yi He
Journal:  J Neurol       Date:  2013-08-30       Impact factor: 4.849

Review 6.  Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance.

Authors:  Dena G Hernandez; Xylena Reed; Andrew B Singleton
Journal:  J Neurochem       Date:  2016-04-18       Impact factor: 5.372

Review 7.  A Practical Approach to Early-Onset Parkinsonism.

Authors:  Giulietta M Riboldi; Emanuele Frattini; Edoardo Monfrini; Steven J Frucht; Alessio Di Fonzo
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.568

Review 8.  The Role of α-Synuclein and LRRK2 in Tau Phosphorylation.

Authors:  Fumitaka Kawakami; Takafumi Ichikawa
Journal:  Parkinsons Dis       Date:  2015-04-21

Review 9.  Genetics of Parkinson's disease - a clinical perspective.

Authors:  Sang-Myung Cheon; Lilian Chan; Daniel Kam Yin Chan; Jae Woo Kim
Journal:  J Mov Disord       Date:  2012-10-30

Review 10.  LRRK2: cause, risk, and mechanism.

Authors:  Coro Paisán-Ruiz; Patrick A Lewis; Andrew B Singleton
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.